Vyora Wellness review
One price, one line
Five longevity products, five flat monthly prices, no membership underneath and no prepay ladder to decode.
Our verdict
Vyora publishes the cleanest peptide pricing in this batch. Sermorelin $189.00 a month, NAD⁺ $189.00, glutathione $159.00, GHK-Cu cream $199.00, tesamorelin $279.00 — one figure per product page, no membership stacked underneath, no six-month prepay masquerading as a monthly rate, and a stated policy that the price does not change when your dose does. It is LegitScript certified and states 503A pharmacy partners. Two things to hold against it: no state list is published, and the shelf reaches further than the evidence does, most obviously with tesamorelin, an approved drug for one specific condition being sold for body composition generally.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. This never affects our rankings or verdicts. How we make money.
At a glance
- Category
- Peptide telehealth
- Access
- NAD⁺ injections $189.00/mo flat, with the price stated as unchanged by dose adjustment; no membership fee, state list not published
- Insurance
- Cash-pay, no insurance
- Visit
- Quiz intake
- Availability
- Not published; confirmed at intake
- LegitScript
- Certified
- Updated
- August 2026
Popular alternative
Oak Longevity
Low-cost sermorelin within a broader longevity stack
Check Oak Longevity availability →What it is
Vyora Wellness is a physician-led telehealth service organised into four categories: Weight Loss (compounded semaglutide and tirzepatide as injections and dissolving tablets, a micro-dosing tirzepatide option, a lipotropic MIC B12 injection and metformin), Longevity & Anti-Aging (sermorelin, NAD⁺, glutathione, tesamorelin), Topicals (a GHK-Cu copper-peptide cream) and supportive products including ondansetron. It is LegitScript certified and states it partners with US-based 503A certified pharmacies.
How it works
Asynchronous and program-shaped, with a clear four-step path the site sets out plainly: choose a treatment or take an assessment, complete a secure medical intake, have a licensed provider review eligibility and — if approved — send the prescription to a regulated US pharmacy, then continue with ongoing care and community support. Two structural commitments do real work. The pricing policy is stated in the company's own words — the price you see is the price you pay, regardless of dosage adjustment — which removes the dose-escalation surcharge that catches people out on peptide and GLP-1 plans elsewhere. And it says it provides organised documentation to support insurance reimbursement submissions while not itself billing insurance, which is an honest framing of what a cash-pay service can actually do for you. What is missing is geography and identity: no list of states it can treat you in appears anywhere, so eligibility is settled during intake, and while 503A pharmacy partners are asserted, none is named and no individual clinician or medical director is published. Insurance is not accepted or required, though HSA and FSA funds have been used toward fees.
Pricing transparency
The clearest in this slice, and structured the way this board wants. Each longevity product page carries a single per-month figure: sermorelin injections $189.00 a month, NAD⁺ injections $189.00, glutathione injections $159.00, tesamorelin $279.00 and the GHK-Cu topical cream $199.00. There is no membership, no consultation fee stacked on top and no prepay tier being presented as a monthly rate — a rarity worth stating outright, because roughly half the providers in this batch quote a number that turns out to require something else. The flat-price commitment extends across dose changes, which for a growth-hormone secretagogue titrated upward over months is where the real savings sit. Two contextual notes and neither is a peptide price: its compounded GLP-1 line runs $299 a month for semaglutide and $399 for tirzepatide, sold as four-week subscriptions, with coaching, nutritional guidance and community access stated as included; and its micro-dosing tirzepatide is an eight-week subscription. Confirm what a month's peptide shipment contains in milligrams, because dose and vial size are not stated beside any longevity price.
Branded vs compounded
Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Vyora states its medications are dispensed through 503A certified US pharmacies, which describes the facility's regulatory category rather than any approval of the preparation, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. No individual pharmacy is named. On the evidence, the five longevity products are five different propositions despite sharing a pricing format. Sermorelin is a GHRH analogue prompting your own pituitary to release growth hormone — a real mechanism with thin long-term human outcome data. Tesamorelin is the one with an approval behind it, and the approval is narrow: it is approved for HIV-associated lipodystrophy specifically, so prescribing it for general visceral fat reduction is off-label use of an approved molecule and should be discussed as such. Injected NAD⁺ has no controlled human outcome trials; oral NR and NMN are the studied forms and raise a blood level. GHK-Cu and injectable glutathione have essentially no controlled human outcome data behind the collagen, skin and detoxification claims made for them. Individual results vary.
Pros and watch-outs
What we like
- A single flat per-month price on every longevity product page, with no membership underneath
- Sermorelin $189.00/mo, NAD⁺ $189.00/mo, glutathione $159.00/mo, GHK-Cu cream $199.00/mo, tesamorelin $279.00/mo
- The price is stated as unchanged by dose adjustment, so titrating upward does not raise the bill
- LegitScript certified, with 503A certified US pharmacy partners stated
- Provides organised documentation to support insurance reimbursement submissions, and accepts HSA/FSA funds
Watch-outs
- No list of states served is published — eligibility is only settled during intake
- Dose and vial size are not stated beside any longevity price
- No compounding pharmacy, individual clinician or medical director named
- Tesamorelin is approved only for HIV-associated lipodystrophy, so this use is off-label
- Its GLP-1 line bills on four-week rather than monthly cycles, which is thirteen charges a year
Best for
People who want one honest monthly figure per peptide, unchanged by dose, with no membership or prepay tier attached.
Who should look elsewhere
Anyone who needs to confirm state eligibility before intake, or who wants the milligrams stated before paying.
The evidence behind what Vyora Wellness prescribes
We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.
- Sermorelin: a real GHRH drug, read against the anti-aging pitch
An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.
- Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence
A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.
- GHK-Cu: the copper peptide between real skincare and overclaim
A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.
- NAD+ precursors (NR and NMN): what the human trials actually show
They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.
- NAD injections: how to get them near you or online, and what the evidence really says
Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.
- Glutathione: the master antioxidant, and where the evidence actually is
Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.
How Vyora Wellness compares
A few alternatives worth a look, depending on what you’re optimizing for.
- WePeptideRx
NAD⁺ buyers who want milligrams, cadence and supply length stated before they compare a price
See WePeptideRx → - Vytora Health
NAD⁺ from a platform that names its pharmacies and its physician group and folds everything into one figure
See Vytora Health → - VigorMeds
Buyers who want NAD⁺ strengths and routes stated, and who will challenge the FDA-approval label before ordering
See VigorMeds →
Pharmacology & mechanisms · Reviewed and last verified August 2026
How we assessed this. This review reflects Aminoscope’s own read of Vyora Wellness’s publicly-stated model — pricing transparency, clinical oversight, medication clarity, and access — against our editorial methodology. We publish no fabricated ratings or first-hand outcomes. A partnership never changes the assessment — see how we make money.
Frequently asked
- What do Vyora's peptides cost?
- Each product page carries one flat per-month figure: sermorelin $189.00, NAD⁺ $189.00, glutathione $159.00, GHK-Cu cream $199.00 and tesamorelin $279.00. There is no membership fee, no consultation charge on top and no prepay tier presented as a monthly rate.
- Does the price go up as my dose increases?
- Vyora states it does not — the price you see is the price you pay, regardless of dosage adjustment. For a peptide titrated upward over months, that is where the structure actually saves you money compared with a per-milligram seller.
- Should I be cautious about tesamorelin?
- It deserves a conversation. Tesamorelin is an approved drug, but approved specifically for HIV-associated lipodystrophy — prescribing it for general visceral fat reduction is off-label use of an approved molecule. Raise that framing with the prescribing provider rather than treating the approval as covering this use.
- Which states does it serve?
- It does not publish a list, so coverage is confirmed during intake. That is the main friction point here, since you complete a medical questionnaire before finding out whether you are eligible.